Palantir stock consolidates as UK government review of NHS data contract keeps price in tight band

Traders Union
All News
Financial News
Palantir slides 0.90% today on UK risk

Highlights

Palantir faces contract and revenue uncertainty as the UK reviews its NHS agreement, with possible early termination in 2027 due to political and regulatory concerns.
Heightened scrutiny over reliance on U.S. technology firms and patient data protection underscores rising regulatory risks to Palantir’s UK public sector business.
PLTR trades below key moving averages with persistent seller momentum, likely remaining within a $123.21 to $140.21 range barring a decisive technical breakout.

Heightened contract risk as UK reviews NHS deal under political pressure

The United Kingdom's review of its National Health Service contract with Palantir Technologies, including possible early termination in 2027, has introduced contract and revenue risk for the company. This review was prompted by mounting political pressure, concerns about dependence on a U.S. technology supplier, and debate over patient data protection and value for money. Confirmation of the review at the parliamentary level and explicit warnings about risks from over-reliance on foreign companies have heightened regulatory uncertainty for Palantir’s position in the UK public sector.

Strong sell momentum persists as multiple indicators flag resistance

PLTR is trading below the MA-20 level at $133.96 and the MA-50 at $141.01 on the working timeframe, with the MA-200 far above at $160.84 on the daily chart. The next technical resistance is at the Ichimoku Kijun level of $134.66. On the momentum side, MACD and ADX both signal a strong sell, while the RSI is at 36.91 and CCI also points to selling conditions. Stoch RSI shows overbought intraday, contrasting with an oversold BBP print, reflecting persistent seller dominance in the short term. The Awesome Oscillator (AO) is neutral, not aligning with directional bias, and a divergence between oscillator exhaustion and underlying seller momentum is apparent.

High downside risk forecast as volatility defines near-term range

Looking ahead to the next 2–3 trading days, the projected price range for PLTR is $123.21 to $140.21, reflecting typical volatility relative to current levels. Downside probability is rated very high, with a baseline scenario for the stock to remain within this band. Should PLTR break above the $134.66 resistance, an upward move might develop, while a fall below $123.21 could trigger further declines.

Viktoras Karapetjanc, analyst at Traders Union, sees Palantir’s UK contract review as a clear source of headline risk but not a fundamental game changer for the company. He notes that the political scrutiny and regulatory questions are driving short-term sentiment, yet the broader demand for data platforms in health systems remains strong. Technical signals are negative for now, but the longer-term outlook is supported by recurring government contracts and sector growth. 'Despite near-term downside pressure and political noise, I view any further declines toward $123.21 as a tactical opportunity for medium-term investors.'

Previously it was reported that ongoing regulatory scrutiny and contract uncertainty in the UK posed significant risks to Palantir’s public sector revenue outlook. The latest confirmation of parliamentary-level review and persistent technical weakness reinforce a cautious stance, with traders advised to monitor the $134.66 resistance and $123.21 support as the next catalysts for a directional move.

Source of Data: PLTR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.